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Clinicopathologic Features of Early Lesions of Cutaneous Follicular Lymphoma,
Diffuse Type. Implications for Early Diagnosis and Treatment
L Cerroni
Department of Dermatology, Medical University of Graz, Austria
The new classification of primary cutaneous lymphomas published by the World
Health Organization (WHO) and the European Organization for Research and
Treatment of Cancer (EORTC)-Cutaneous Lymphoma Task Force includes primary
cutaneous follicular B-cell lymphoma (PCFBCL) as a distinct entity characterized by
either a follicular, diffuse, or mixed pattern of growth. Although the diffuse type of
PCFBCL shows histologically predominance of large cleaved cells, thus revealing
similarities to the histopathologic picture of the large B-cell lymphomas, prognosis
and treatment are similar to those of PCFBCL variants characterized by a follicular
or a mixed pattern of growth, thus underlying the need to classify all variants in one
and the same group. It is yet unclear, whether cases with diffuse pattern of growth
represent a morphologic ‘‘progression’’ of follicular cases, or if they present with a
diffuse pattern of growth from the onset. We have observed in the last years several
patients with PCFBCL, diffuse type, and studied the clinical and histopathologic
features of early lesions (flat lesions, small papules). A clear-cut follicular pattern
was always absent, and remnants of CD21þ follicular dendritic cells were present
in less than half of the cases, suggesting that in most instances the growth pattern is
diffuse from the beginning. Other phenotypic aspects were similar to those of the
more advanced (tumoral) lesions, characterized by positivity for CD20 and Bcl-6,
and negativity or only focal positivity for Bcl-2 and MUM-1. In several cases we
observed small papular lesions located far away (410 cm) from the main area of
involvement, demonstrating that neoplastic cells were present well beyond the
clinically apparent lesion. This finding has implications on the management of
these patients, as local radiotherapy does not cover the area distant from the
primary tumor, thus resulting in incomplete treatment and high risk of recurrence.
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Molecular Analysis of Cutaneous B-cell Lymphoma: Relevance for Diagnosis and
Treatment
R Willemze
Department of Dermatology; Leiden University Medical Center, Leiden, The
Netherlands
Recent molecular genetic studies have contributed significantly to a better
definition of the different types of cutaneous B-cell lymphomas (CBCL) and
consequently to a new consensus classification for these CBCL. In this WHO-
EORTC classification three main types of CBCL are distinguished: primary
cutaneous marginal zone B-cell lymphoma, primary cutaneous follicle center
lymphoma (PCFCL) and primary cutaneous large B-cell lymphoma, leg type
(PCLBCL- LT). For many years differentiation between PCFCL with a diffuse
infiltrate of large B-cells and PCLBCL, LT was controversial. Distinction between
these two groups is however important because of their different prognosis (disease-
related 5-year survival of 95% and 50%, respectively) and different first choice of
treatment (radiotherapy versus systemic chemotherapy, respectively). Recent
studies showed that these PCFCL have the gene expression profile of germinal
center-like B-cell lymphomas, while PCLBCL-LT have the gene expression profile
of activated B-cell type diffuse large B-cell lymphomas. Consistently, PCLBCL-LT
strongly express the activated B-cell markers Mum-1/IRF-4 and FOX-P1. Array-
based CGH studies and FISH analysis showed c-REL amplification in ca. 70% of
PCFCL, which provides further support for their germinal center cell origin. In
contrast to these PCFCL, PCLBCL-LT showed high-level amplifications of both the
MALT-1 gene and the BCL-2 gene, which may explain the strong bcl-2 protein
expression in these lymphomas, as well as deletion of a small region within 9p21.3
containing the CDKN2A gene. Inactivation of CDKN2A either by deletion or by
promoter hypermethylation was strongly associated with a poor prognosis, and may
be used as an important adjunct in selecting appropriate treatment in patients with
a PCLBCL-LT.
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Molecular Studies in CTCL: Relevance for Diagnosis and Treatment
S Whittaker
St Johns Institute of Dermatology, Guys and St Thomas Hospital, London, United
Kingdom
Significant progress has been made in the development of molecular techniques
which help the diagnosis of CTCL but tumour specific markers have yet to be
clearly identified. There is also a need to measure disease response in a consistent
manner and to identify specific molecular therapeutic targets.
While TCR gene analysis can identify identical T-cell clones in different tissues
from patients, this technique has a high false negative rate in early stage disease
when diagnostic problems occur and the prognostic relevance has yet to be fully
established in mycosis fungoides. Recent studies have identified relative T-cell
immunodeficiency and abnormalities of regulatory T-cell function in CTCL which
has critical therapeutic consequences. Studies of gene expression have shown
abnormal cDNA expression patterns which may distinguish inflammatory
dermatoses from mycosis fungoides and Sezary syndrome (SS). These gene
expression patterns may also explain the variable response to different therapies
such as alpha interferon. A recent study suggests that a gene signature pattern of 5
genes (STAT4, GATA-3, PLS3, CD1d and TRAIL) can be reliably used to diagnose
SS. Furthermore aberrant RNA and protein expression of one of these genes, T-
Plastin (PLS3), is a potential tumour marker and therapeutic target in SS although
the functional relevance of aberrant T-Plastin expression has yet to be established.
Malignant cells arise from a combination of DNA mutational and epigenetic
abnormalities which perturb gene function. In CTCL there is emerging evidence
that epigenetic abnormalities such as promotor hypermethylation and histone
modification may be common mechanisms of gene dysregulation particularly in
early stage disease. Importantly such changes are now amenable to therapeutic
intervention with agents such as histone deactylase (HDAC) inhibitors. There are
currently several trials assessing the use of HDAC inhibitors in CTCL and it should
be possible to predict patient response at the molecular level.
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EORTC Guidelines for the Treatment of Mycosis Fungoides/Sezary Syndrome
R Knobler
Medical University of Vienna, Division of Special and Environmental Dermatology,
Vienna, Austria
There are a number of published reviews and guidelines for the management of
mycosis fungoides (MF) and Sezary syndrome (SS) but there are no uniform
treatment guidelines arriving to an European consensus. For this reason the
European Organization for Research and Treament of Cancer (EORTC), cutaneous
lymphoma task force (CLTF), undertook the task of summarizing the available
evidence and review ’best practices’ from each national group in order to establish
European guidelines for the treatment of MF/SS. Guidelines were formulated
according to the quality of supporting data as defined by the Oxford Centre for
Evidence-Based Medicine. Skin-directed therapies are the most appropriate option
for early stages disease with good prognosis. Patients with advanced disease should
participate in clinical trials whereby maintenance of quality of life should the
guiding principle.
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Optimizing the Systemic Treatment of CTCL
N Pimpinelli
Department of Dermatological Sciences, University of Florence Medical School,
Florence, Italy
Systemic treatment is indicated in refractory, advanced, or aggressive Cutaneous T
Cell Lymphoma (CTCL). Notwithstanding no single agent, combination or
sequential regimen have demonstrated a high benefit/risk profile and considering
that some drugs are not yet available in Europe, the scenario has substantially
changed in the last few years according to many clinical studies (most of them non-
randomized and non-controlled). Oral bexarotene is a valid alternative option both
in stage I-IIA mycosis fungoides (MF) patients refractory (or plurilapsed after) skin-
directed treatments and in advanced stage (IIB-IV) MF and Sezary syndrome (SS)
patients refractory to or relapsing after a first line of systemic treatment. The role of
bexarotene in patients in CR/PR/SD after a first line of systemic treatment is
currently under evaluation. Monochemotherapy (gemcitabine, pegylated liposomal
doxorubicin) is a valuable first line therapeutic option for patients with stage IIB and
stage III MF or SS , as an alternative to radiotherapy (TSEBI þ / superficial
radiotherapy), PUVA/IFN, and extracorporeal photochemotherapy, respectively.
Alemtuzumab is a further, alternative or sequential option for stage III MF and SS
patients. As a rule, polychemotherapy is not recommended for first-line treatment
of stage IIB-III MF, due to lacking advantages in terms of DFS and OS, the high risk
of immunosuppression, and the relevant reduction in quality of life. Patients who
are refractory to or relapsing after at least two lines of systemic treatment should be
considered for high-dose chemotherapy and stem cell transplantation.
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